RIGL - Rigel Pharmaceuticals Inc

Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat blood disorders, cancer, and rare immune diseases. The company is headquartered in South San Francisco, California.

52W High

$43.72

52W Low

$12.66

MA Status:

50D: Above 200D: Above

Beta (~1 neutral, <0.9 lower risk)

1.27

Valuation

Attractive

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

7.61

Forward P/E (<15 better)

7.15

EV/EBITDA (<8 favorable)

6.35

EV/Revenue (<3 favorable)

2.59

P/S (TTM) (<3 favorable)

2.77

P/B (<3 favorable)

9.05

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

2.65%

Institutions (25–75% balanced)

78.67%

Shares Outstanding

17,937,300

Float

16,084,800

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

267,921,000

Gross Profit (TTM)

221,813,000

EPS (TTM)

5.43

Profit Margin (>10% good)

0.37%

Operating Margin (TTM) (higher better)

0.60%

ROE (TTM) (>15% strong)

0.38%

EPS YoY (Quarterly) (>10% good)

17.87

Revenue YoY (Quarterly) (>8% good)

1.76

Momentum

Bearish momentum

Value

2.0572

2.2879

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025